RAC 0.31% $1.60 race oncology ltd

I speculate that RAC have a background activity working on an...

  1. 11,249 Posts.
    lightbulb Created with Sketch. 29637
    I speculate that RAC have a background activity working on an oral formulation combining Zantrene and ASTX727 (note ASTX747 is a typo).

    https://www.asx.com.au/asxpdf/20211101/pdf/452fm1vcm8f2j0.pdf

    Screen Shot 2021-12-16 at 12.01.11 pm.png

    https://astx.com/research-developme...azuridine-astx727-hematological-malignancies/

    Otsuka have their own program developing an oral combination - from the above link:

    Screen Shot 2021-12-16 at 12.09.23 pm.png
    So I'm wondering if there will be an oral formulation combining decitabine, cedazuridine and Zantrene once data to help determine optimal dosage is generated.

    Screen Shot 2021-12-16 at 12.16.39 pm.png
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.